Use of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic


ABSTRACT: Introduction: Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers are promising tools to help identify the underlying pathology of neurocognitive disorders. In this manuscript, we report our experience with AD CSF biomarkers in 262 consecutive patients in a tertiary care memory clinic. Methods: We retrospectively reviewed 262 consecutive patients who underwent lumbar puncture (LP) and CSF measurement of AD biomarkers (Aβ1–42, total tau or t-tau, and p-tau181). We studied the safety of the procedure and its impact on patient’s diagnosis and management. Results: The LP allowed to identify underlying AD pathology in 72 of the 121 patients (59%) with early onset amnestic mild cognitive impairment (aMCI) with a high probability of progression to AD; to distinguish the behavioral/dysexecutive variant of AD from the behavioral variant of frontotemporal dementia (bvFTD) in 25 of the 45 patients (55%) with an atypical neurobehavioral profile; to identify AD as the underlying pathology in 15 of the 27 patients (55%) with atypical or unclassifiable primary progressive aphasia (PPA); and to distinguish AD from other disorders in 9 of the 29 patients (31%) with psychiatric differential diagnoses and 19 of the 40 patients (47%) with lesional differential diagnoses (normal pressure hydrocephalus, encephalitis, prion disease, etc.). No major complications occurred following the LP. Interpretation: Our results suggest that CSF analysis is a safe and effective diagnostic tool in select patients with neurocognitive disorders. We advocate for a wider use of this biomarker in tertiary care memory clinics in Canada.

RÉSUMÉ : Utilisation dans une clinique de la mémoire des biomarqueurs du liquide cérébrospinal dans des cas de patients atteints de la maladie d’Alzheimer. Introduction : Dans le cas de la maladie d’Alzheimer (MA), les biomarqueurs du liquide cérébrospinal (LCS) constituent des outils prometteurs pour identifier la pathologie sous-jacente des troubles neurocognitifs. Dans cet article, nous voulons faire état de notre expérience avec ces biomarqueurs chez 262 patients vus consécutivement dans une clinique de la mémoire. Méthodes : Nous avons ainsi passé en revue rétrospectivement les dossiers de 262 patients qui avaient subi une ponction lombaire (PL) et chez qui l’on avait quantifié les biomarqueurs du LCS (protéine amyloïde A1-42, protéine Tau totale et protéine Tau 181). Nous avons aussi évalué la sécurité de cette procédure ainsi que son impact sur la prise en charge des patients et leur diagnostic. Résultats : Les PL ont permis d’identifier une pathologie sous-jacente à la MA chez 72 patients sur 121 (59 %), à savoir des troubles cognitifs légers (TCL) de nature amnésique apparaissant à un stade précoce et dont la probabilité de progresser vers la MA était élevée. Qui plus est, cet examen a permis de distinguer la variante comportementale/dysexecutive de la MA de la variante comportementale de la démence fronto-temporale chez 25 patients sur 45 (55 %) dont le profil neurocomportemental était atypique. Il a également permis d’identifier la MA comme pathologie sous-jacente chez 15 patients sur 27 (55 %) atteints d’aphasie primaire progressive atypique ou inclassable et de distinguer la MA d’autres troubles chez 9 patients sur 29 (31 %) ayant reçu un diagnostic psychiatrique différentiel et chez 19 patients sur 40 (47 %) ayant reçu des diagnostics différentiels de lésions (hydrocéphalie à pression normale, encéphalite, maladies à prions, etc.). Il est à noter qu’aucune complication majeure n’est survenue à la suite de PL. Interprétation : Nos résultats donnent à penser que des analyses menées au moyen des PL sont des outils diagnostics sécuritaires chez certains patients atteints de troubles neurocognitifs. Nous plaiddons donc pour une utilisation plus large des biomarqueurs du LCS dans les cliniques de la mémoire au Canada.

Keywords: Alzheimers, FDG-PET, Neuropsychology, Behavioral Neurology, Cerebrospinal Fluid, Biomarker
doi:10.1017/cjn.2021.67
**Introduction**

Lumbar puncture (LP) is a simple technique to sample cerebrospinal fluid (CSF) as a window into central nervous system (CNS) biochemistry. A large body of literature now suggests that a biological diagnosis of Alzheimer’s disease (AD) can be made using measurements of pathogenic proteins in the CSF.\(^1\) We have known for more than 25 years that decreased amyloid β levels in CSF reflect aggregation into plaques of cerebral amyloid β – a core feature of AD pathological diagnosis;\(^6\) and that high levels of microtubule-associated protein tau in CSF reflect axonal pathology in AD.\(^5\)\(^\_8\) CSF analysis is now recognized as a reliable diagnostic tool for AD in NIA-AA and IWG-2 diagnostic criteria;\(^6,9\) and is widely used in European academic memory clinics.\(^10\)\(^\_14\) In Canada, CSF samples are collected in academic dementia centers as part of the Alzheimer’s Disease Neuroimaging Initiative (ADNI),\(^15\) but the clinical use of CSF analysis in neurocognitive diseases remains scarce to this date.\(^10\)\(^\_14\)\(^,16\) In our experience, CSF analysis is a useful tool to reach an earlier and more accurate diagnosis in patients with early onset atypical dementia, for whom the initial dementia workup did not allow to reach a clear diagnosis. In this manuscript, we report our clinical experience with CSF analysis in the diagnostic workup of 262 consecutive patients seen at our tertiary care memory clinic.

**Methods**

**Patient Selection and Diagnostic Workflow**

The Clinique Interdisciplinaire de Mémoire du CHU de Québec (CIME) is the oldest memory clinic in Canada.\(^17\) It is visited by an average of 1500 patients per year, generally for further evaluation after an inconclusive initial assessment by a primary care physician. All patients were assessed according to the “Recommendations of the 4th and 5th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia.” Initial consultation typically includes history-taking, physical examination, cognitive screening, targeted cognitive screening, basic blood work, and brain imaging with computed tomography or magnetic resonance imaging (MRI). In our experience, this initial diagnostic workup allows to reach a probable diagnosis in about 70% of patients.\(^18\)\(^,19\) When diagnosis remains unclear, patients can be referred to further neuropsychological testing or 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). When the diagnosis is still unclear, clinicians can repeat FDG-PET\(^15\) or order either an amyloid PET\(^18\) or an LP with CSF analysis of AD biomarkers (see Figure 1).

**Lumbar Puncture and Cerebrospinal Fluid Analysis**

All LPs were performed by three experienced neurologists (LV, RWB, RL) according to the Canadian and International Guidelines.\(^16\)\(^,20\)\(^-\)\(^22\) We collected a total of 5-20 ml of CSF divided into three to four sterile polypolyethylene tubes of approximately 10ml of CSF each: (1) cell count; (2) glucose, proteins; (3) AD biomarkers; and (4) further infectious and/or autoimmune investigation in select cases. Traumatic taps causing blood contamination of CSF were not used for biomarker study. Patients remained supine for 15–30 min, followed by progressive mobilization. All polypolyethylene tubes identified for AD biomarker analysis were centrifuged at 2000×g for 10 min at room temperature within 15 min of LP. They were split into 2 ml aliquots in small polypolyethylene tubes and kept at −80 °C using dry ice. One 2 ml tube was sent overseas by express mail on dry ice to Amsterdam VUmc Alzheimercentrum for AD biomarker analysis. Other 2 ml was stored locally at −80 °C. Aβ-42, total tau (t-tau), and tau phosphorylated at threonine 181 (p-tau\(_{181}\)) concentrations were measured with INNO-BIA AlzBio3 Luminex assay (Fujirebio, formerly Innogenetics, Gent, Belgium). All CSF analyses were performed at the end of the study at the VUmc in Amsterdam in the Netherlands. Reference values were >640 pg/ml for Aβ-42, <375 pg/ml for t-tau, and <52 pg/ml for p-tau\(_{181}\) according to single-center validation studies.\(^23\)\(^-\)\(^25\) Due to the upward drift of Aβ-42 values measured with Innostest ELISA over the past two decades (caused by changes in ELISA kits over time), reference values for Aβ-42 changed over time, first >550 pg/ml, then >640 pg/ml, >680 pg/ml, then >1000 pg/ml.\(^26\) An AD CSF profile was established when Aβ-42 was lowered and at least one tau measurement was elevated. When absolute values were at the limit of positivity, a ratio of p-tau:Aβ-42 was calculated to facilitate interpretation of the results; a ratio exceeding 0.024 was considered suggestive of Alzheimer’s pathophysiology.

**Data Collection and Statistical Analyses**

For all patients, we retrospectively retrieved the following variables: age at the time of LP, sex, number of years of education, MMSE score/30 closest to LP (<6 months), date of LP, Aβ-42, t-tau, and p-tau\(_{181}\) level, minor and/or major complications of LP (minor: post-LP headache, minor infection not requiring antibiotics; major: CNS infection requiring antibiotics, significant bleeding, post-LP headache requiring blood patch, etc.), date of amyloid PET if applicable, visual read of amyloid PET (positive/negative), concordance between LP and amyloid PET, primary and alternative diagnoses prior to LP, primary and alternative diagnoses following LP, change in diagnosis and/or management following LP. Analyses were performed using SPSS (version 22; IBM, Chicago, IL, USA) and STATA (version 14; StataCorp; College Station, TX, USA). Differences in

---

**Figure 1:** Diagnostic workup at Clinique Interdisciplinaire de Mémoire du CHU de Québec, a tertiary care memory clinic in Quebec City, QC, Canada.
demographical characteristics were assessed using ANOVA for continuous variables and \( \chi^2 \) or Mann-Whitney \( U \) tests for dichotomous or categorical data.

**RESULTS**

**Patient Characteristics**

Between July 2015 and April 2020, 3755 patients were evaluated at the CIME tertiary care memory clinic; in 262 patients (7%), an LP was performed to help clarify the diagnosis of the neurocognitive disorder. In these patients, the initial memory clinic workup, including history taking, neurological examination, cognitive testing, blood tests, MRI, and FDG-PET did not allow to reach a clear diagnosis. Patient characteristics are shown in Table 1. Patients were on average young (67.5 ± 2 years old), well-educated (12.7 ± 2 years of education), and at an early disease stage (MMSE 26 ± 3). Indication for LP covered a wide range of clinical scenarios (see Figure 2). Over the 262 LP, 121 (46%) were ordered to identify underlying AD pathology in patients with amnestic mild cognitive impairment (aMCI) with a high probability of progression to AD, 45 (17%) were ordered to distinguish the behavioral variant of frontotemporal dementia (bvFTD) from the dysexecutive variant of AD, 27 (10%) to identify the underlying pathology in primary progressive aphasia (PPA) with mixed/unclassifiable features, 29 (11%) to differentiate AD from psychiatric conditions (depression, psychotic disorder, attentional disorders, bipolar disorder, etc.), and 40 (15%) to distinguish AD from other conditions.

**CSF Results**

In the total cohort, 140 out of 262 (53%) patients had lowered Aβ-42 levels compared to 122 patients with normal Aβ-42 levels. Of those, 49 out of 101 (49%) patients 65 years old or less were amyloid-positive compared to 91 out of 151 (56%) older than 65 years old. Seven patients had both CSF analysis and amyloid PET results. CSF and amyloid PET were concordant in 67/67(86%) of cases for amyloid β status. The discordant case was a patient with chronic alcohol use, depression, and a clinical suspicion of AD whose amyloid PET was negative, CSF Aβ-42 was borderline (550 pg/ml), and t-tau and p-tau181 was normal (163 pg/ml).

**Impact on Diagnosis and Management**

The LP was performed to rule out the presence of AD pathology in 121 patients with aMCI (mean MMSE 26.7). The LP showed a CSF profile consistent with AD pathophysiology in 72/121 patients (59%); these patients were diagnosed with aMCI due to AD pathology and treatment with acetylcholinesterase inhibitor was initiated. The 49 patients with normal CSF profiles were reassured that the LP did not reveal changes consistent with AD, and that patients with amyloid-negative MCI generally have a better cognitive prognosis. In patients with an atypical cognitive profile or abnormal FDG-PET, an alternative neurodegenerative pathology was considered. One patient received a diagnosis of bvFTD and a second diagnosis of primary age-related tauopathy (PART).

The LP was performed in 45 patients to distinguish AD versus FTD pathology in patients with atypical behavioral presentation. The LP showed a CSF profile consistent with AD pathophysiology in 25/45 (55%) of patients, leading to a diagnosis of behavioral/dysexecutive AD. 20/45 patients were amyloid-negative. Seventeen patients were diagnosed with bvFTD, one with corticobasal syndrome, and two patients had uncertain diagnoses at the time the charts were analyzed. The LP leads to a change in the primary diagnosis in 23 (51%) of the cases.

The LP was performed in 27 patients with PPA and a clinicoanatomical syndrome, which did not allow confident classification among one of the three variants. The LP showed a CSF profile consistent with AD pathophysiology in 15/27 (55%) of patients, leading to a diagnosis of AD with language presentation (logopenic variant of PPA or mixed PPA due to AD). 12/27 patients were amyloid-negative and was diagnosed with PPA due to FTD pathology. More specifically, amyloid-negative patients were diagnosed with the semantic (four patients) and non-fluent (four patients) variants of PPA, primary progressive apraxia of speech (one patient), and subjective memory complaints (three patients).

In 40 patients, the LP was performed to distinguish AD from other disorders like vascular dementia, normal pressure hydrocephalus, paraneoplastic encephalitis, LGG1 encephalitis, prion

---

**Table 1: Demographics of the sample**

<table>
<thead>
<tr>
<th></th>
<th>Full cohort</th>
<th>Amnestic MCI group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients (n, %)</td>
<td>262 (100%)</td>
<td>113 (43%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>67.5 ± 9</td>
<td>68.0 ± 3</td>
</tr>
<tr>
<td>Female (n, %)</td>
<td>128 (49%)</td>
<td>63 (56%)</td>
</tr>
<tr>
<td>Education (no. of years)</td>
<td>12.7 ± 2</td>
<td>13.1 ± 6</td>
</tr>
<tr>
<td>MMSE score (/30)</td>
<td>26 ± 3</td>
<td>27 ± 2</td>
</tr>
<tr>
<td>Amyloid positivity (n, %)</td>
<td>140 (53%)</td>
<td>67 (59%)</td>
</tr>
</tbody>
</table>

MCI = mild cognitive impairment.
The 20 patients with normal CSF prodiagnosis of AD with neuropsychiatric symptoms was made. CNS infection, hematoma, or brain herniation.

patch (six) and back pain (three). No patients had an iatrogenic
tions such as temporary positional headache not requiring blood
aches requiring a blood patch. Nine patients had minor complica-
ations of post-LP complaints. Of course, less invasive biomarkers
(such as blood biomarkers) would represent preferable diagnostic
tools; however, the blood-brain barrier makes it difficult to
identify CNS proteins in the blood in sufficient levels to reach
acceptable diagnostic accuracy for clinical use. Some high-
hidity assays have shown reasonable correspondence with CSF
amyloid and tau levels, but their accuracy would currently allow
for pre-screening at best.

Diagnostic Properties of CSF Biomarkers and Comparison with Amyloid PET

In this study, the strong diagnostic impact of CSF analysis was
derived from the assumption that CSF Aβ-42, t-tau, and p-tau181
reliably reflect AD neuropathology; gold-standard autopsy con-
firmation was not available in any patient. Converging evidence
has highlighted the inverse correlation between CSF Aβ-42 and
cerebral Aβ plaques at autopsy or brain biopsy in healthy
controls, MCI, AD, and non-AD dementias. CSF t-tau and
p-tau181 were also shown to correlate with neocortical tangle
pathology at autopsy or brain biopsy. Subsequently, the
emergence of PET Aβ and Tau ligands have enabled visualiza-
tion of Aβ plaques in the brain in living patients. Concord-
dance between amyloid positivity shown by CSF Aβ-42 and
amyloid PET has consistently remained around 90% regardless
of the ligand. In MCI, abnormal CSF Aβ-42, t-tau, and p-tau181
status has been associated with higher prevalence and faster pace of
conversion from MCI to AD.

Limitations and Future Perspectives

Limitations of the use of CSF analysis in tertiary care memory
clinics include the invasiveness of the technique, the risk of minor
and major complications, the lack of harmonization of methods
for the handling of CSF samples, and the upward drift in CSF Aβ-42
values over time due to changes in ELISA kits. Ongoing
multicenter efforts aim to better standardize the handling and
analysis of CSF samples in order to facilitate their widespread
clinical use. We have limitations. Our study was a
retrospective evaluation of the use of LP at our memory clinic.
This implies a significant selection bias, since the LP was
performed only in a minority of patients evaluated at our memory clinic (see Figure 1), when the standard memory clinic workup (clinical and neuropsychological evaluation, lab tests, MRI, FDG-PET) did not allow to reach a clear diagnosis. Nevertheless, our study provides real-world data on the clinical use of CSF analysis in the tertiary care memory clinic. In this study, we only had access to CSF Aβ42, t-tau, and p-tau181 measurements, consistent with international consensus recommendations.37,55 However, the field of CSF-based biomarkers is rapidly evolving, and multiple novel assays are now available to evaluate Aβ metabolism (sAPPα, sAPPβ), Aβ-40, Aβ-38, synucleinopathies (a-synuclein), neurodegeneration (neurofilament, NSE, VLP-1, neurogranin, HFABP), and glial activation (YKL-40, MCP-1, GFAP).15-38 Although validated assays for these new biomarkers are not readily available for clinical practice, they hold great potential to improve diagnostic accuracy in AD, but also in FTD and other neurodegenerative disorders.56,57,69-62 Therefore, while PET currently does not allow the concomitant use of multiple tracers, CSF analysis has the potential to inform us on the homeostasis of a wide range of biological pathways in order to reach a more accurate biological diagnosis of dementia. Finally, some would argue that LP represents an invasive treatment to diagnose disorders for which cannot benefit from disease-modifying treatments. There is evidence, although inconsistent, that initiation of acetylcholinesterase inhibitors early in the disease (even at the MCI stage) can delay the progression to the dementia stage.63-66 Furthermore, in early onset dementia, a timely diagnosis also greatly reduces the anxiety related to the diagnostic uncertainty and allows to better plan for future care.18,66

CONCLUSION

Altogether, our results highlight the safety and clinical utility of CSF biomarkers for the diagnosis of select patients with neurocognitive disorders, and advocate for their increased use in tertiary care memory clinics in Canada.

ACKNOWLEDGMENTS

The authors wish to thank the Primary Progressive Aphasia Research Chair – Lemaire Family Fund at Université Laval and the Vanier Graduate Scholarship of the Canadian Institutes of Health Research (CIHR) for funding this research.

CONFLICT OF INTEREST

We have no competing interests to disclose.

STATEMENT OF AUTHORSHIP

MS and DB contributed equally to this work. DB, MS, and RJrL were involved in study design, data analysis, and drafting the initial version of the manuscript. MS, DB, EP, XR SMD were involved in data collection. KM coordinated the handling of CSF samples. LS, PM YN, MFP, SC, SP, LV RWB, and RJrL are clinicians at the CIME who were involved in implementing CSF analysis as a diagnostic tool for atypical dementia. CT was our main collaborator at VUmc Alzheimercentrum and shared her experience in using CSF analysis for dementia diagnosis. All authors provided input to the manuscript and agreed on the final version of the manuscript.

REFERENCES


frontotemporal dementia identified by proteomics. 


